Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMday Antimicrobial Resistance - registration for academics now open

Events General Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes?

If you answer YES to any of the above, now is the time to register for the AIMday in Antimicrobial Resistance.

The event takes place on Thursday 4 July at the Blavatnik School of Government and is hosted by The University of Oxford, together with the NIHR Community Healthcare MIC.

FREE registration for academics is now open and closes on Thursday 27 June (advance registration is essential).

A range of companies are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions.

Companies registered to attend

  • Abbott
  • Academic Health Science Network for the North East and North Cumbria
  • Amprologix
  • Astrego Diagnostics
  • Centauri Therapeutics
  • Destiny Pharma
  • Evotec
  • GeneFirst
  • GSK
  • Ingenza
  • Innovate UK
  • metaLinear
  • Oppilotech
  • Oxford Drug Design
  • Pedanius Therapeutics
  • Randox Laboratories
  • Release Life Sciences and Diagnostics
  • Summit Therapeutics
  • Thermo Fisher Scientific

To see the questions posed by these companies, please visit aimday.se/amr-2019/questions-listing.

Register here: http://aimday.se/amr-oxford-2019. 

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.